326.47 USD
-2.5 (-0.76%)
AMGN gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 528 industry peers in the Biotechnology industry. AMGN has an excellent profitability rating, but there are concerns on its financial health. AMGN has a decent growth rate and is not valued too expensively. Finally AMGN also has an excellent dividend rating.
1. Profitability
1.1 Basic Checks
- AMGN had positive earnings in the past year.
- AMGN had a positive operating cash flow in the past year.
- Each year in the past 5 years AMGN has been profitable.
- In the past 5 years AMGN always reported a positive cash flow from operatings.
1.2 Ratios
- AMGN has a better Return On Assets (7.77%) than 92.99% of its industry peers.
- Looking at the Return On Equity, with a value of 72.82%, AMGN belongs to the top of the industry, outperforming 99.05% of the companies in the same industry.
- With an excellent Return On Invested Capital value of 15.39%, AMGN belongs to the best of the industry, outperforming 96.02% of the companies in the same industry.
- AMGN had an Average Return On Invested Capital over the past 3 years of 13.04%. This is significantly below the industry average of 18.28%.
- The last Return On Invested Capital (15.39%) for AMGN is above the 3 year average (13.04%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROIC | 15.39% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
1.3 Margins
- AMGN has a Profit Margin of 19.47%. This is amongst the best in the industry. AMGN outperforms 93.18% of its industry peers.
- In the last couple of years the Profit Margin of AMGN has declined.
- AMGN's Operating Margin of 33.57% is amongst the best of the industry. AMGN outperforms 97.16% of its industry peers.
- AMGN's Operating Margin has declined in the last couple of years.
- With an excellent Gross Margin value of 72.06%, AMGN belongs to the best of the industry, outperforming 82.58% of the companies in the same industry.
- In the last couple of years the Gross Margin of AMGN has declined.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% |
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMGN is creating some value.
- AMGN has more shares outstanding than it did 1 year ago.
- AMGN has less shares outstanding than it did 5 years ago.
- Compared to 1 year ago, AMGN has an improved debt to assets ratio.
2.2 Solvency
- The Debt to FCF ratio of AMGN is 4.28, which is a neutral value as it means it would take AMGN, 4.28 years of fcf income to pay off all of its debts.
- With an excellent Debt to FCF ratio value of 4.28, AMGN belongs to the best of the industry, outperforming 92.23% of the companies in the same industry.
- AMGN has a Debt/Equity ratio of 5.45. This is a high value indicating a heavy dependency on external financing.
- Looking at the Debt to Equity ratio, with a value of 5.45, AMGN is doing worse than 80.49% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Altman-Z | N/A |
ROIC/WACC1.8
WACC8.57%
2.3 Liquidity
- A Current Ratio of 1.28 indicates that AMGN should not have too much problems paying its short term obligations.
- Looking at the Current ratio, with a value of 1.28, AMGN is doing worse than 83.14% of the companies in the same industry.
- A Quick Ratio of 0.99 indicates that AMGN may have some problems paying its short term obligations.
- With a Quick ratio value of 0.99, AMGN is not doing good in the industry: 85.42% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 |
3. Growth
3.1 Past
- AMGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 13.79%, which is quite good.
- Measured over the past 5 years, AMGN shows a small growth in Earnings Per Share. The EPS has been growing by 5.97% on average per year.
- Looking at the last year, AMGN shows a quite strong growth in Revenue. The Revenue has grown by 10.56% in the last year.
- The Revenue has been growing slightly by 7.43% on average over the past years.
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
3.2 Future
- AMGN is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.77% yearly.
- Based on estimates for the next years, AMGN will show a small growth in Revenue. The Revenue will grow by 3.63% on average per year.
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
- The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 14.93 indicates a correct valuation of AMGN.
- Compared to the rest of the industry, the Price/Earnings ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 96.21% of the companies listed in the same industry.
- When comparing the Price/Earnings ratio of AMGN to the average of the S&P500 Index (27.33), we can say AMGN is valued slightly cheaper.
- A Price/Forward Earnings ratio of 14.58 indicates a correct valuation of AMGN.
- AMGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. AMGN is cheaper than 96.02% of the companies in the same industry.
- AMGN's Price/Forward Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 24.12.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.93 | ||
| Fwd PE | 14.58 |
4.2 Price Multiples
- Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 95.83% of the companies listed in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of AMGN indicates a rather cheap valuation: AMGN is cheaper than 97.16% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 13.78 | ||
| EV/EBITDA | 12.58 |
4.3 Compensation for Growth
- AMGN's PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
- AMGN has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)1.58
PEG (5Y)2.5
EPS Next 2Y6.31%
EPS Next 3Y5.32%
5. Dividend
5.1 Amount
- With a Yearly Dividend Yield of 3.05%, AMGN has a reasonable but not impressive dividend return.
- AMGN's Dividend Yield is rather good when compared to the industry average which is at 1.26. AMGN pays more dividend than 98.86% of the companies in the same industry.
- AMGN's Dividend Yield is rather good when compared to the S&P500 average which is at 1.91.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
5.2 History
- The dividend of AMGN is nicely growing with an annual growth rate of 9.41%!
- AMGN has been paying a dividend for at least 10 years, so it has a reliable track record.
- AMGN has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)9.41%
Div Incr Years13
Div Non Decr Years13
5.3 Sustainability
- AMGN pays out 17.20% of its income as dividend. This is a sustainable payout ratio.
- The dividend of AMGN is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP17.2%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
NASDAQ:AMGN (1/15/2026, 10:21:00 AM)
326.47
-2.5 (-0.76%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-04 2025-11-04/amc
Earnings (Next)02-03 2026-02-03/amc
Inst Owners83.87%
Inst Owner Change-0.04%
Ins Owners0.06%
Ins Owner Change-0.77%
Market Cap175.80B
Revenue(TTM)35.97B
Net Income(TTM)7.00B
Analysts72.2
Price Target334.67 (2.51%)
Short Float %2.63%
Short Ratio5
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 3.05% |
Yearly Dividend9.01
Dividend Growth(5Y)9.41%
DP17.2%
Div Incr Years13
Div Non Decr Years13
Ex-Date02-13 2026-02-13 (2.52)
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.96%
Min EPS beat(2)10.28%
Max EPS beat(2)11.64%
EPS beat(4)4
Avg EPS beat(4)9.04%
Min EPS beat(4)2.49%
Max EPS beat(4)11.73%
EPS beat(8)7
Avg EPS beat(8)5.13%
EPS beat(12)10
Avg EPS beat(12)4.44%
EPS beat(16)14
Avg EPS beat(16)4.21%
Revenue beat(2)2
Avg Revenue beat(2)2.59%
Min Revenue beat(2)0.68%
Max Revenue beat(2)4.49%
Revenue beat(4)3
Avg Revenue beat(4)1.17%
Min Revenue beat(4)-0.84%
Max Revenue beat(4)4.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.21%
Revenue beat(12)4
Avg Revenue beat(12)-0.48%
Revenue beat(16)5
Avg Revenue beat(16)-0.54%
PT rev (1m)0.48%
PT rev (3m)4.6%
EPS NQ rev (1m)0.13%
EPS NQ rev (3m)-7.7%
EPS NY rev (1m)0.02%
EPS NY rev (3m)0.93%
Revenue NQ rev (1m)-0.02%
Revenue NQ rev (3m)1.04%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.75%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 14.93 | ||
| Fwd PE | 14.58 | ||
| P/S | 4.89 | ||
| P/FCF | 13.78 | ||
| P/OCF | 13.39 | ||
| P/B | 18.28 | ||
| P/tB | N/A | ||
| EV/EBITDA | 12.58 |
EPS(TTM)21.87
EY6.7%
EPS(NY)22.4
Fwd EY6.86%
FCF(TTM)23.69
FCFY7.26%
OCF(TTM)24.38
OCFY7.47%
SpS66.8
BVpS17.86
TBVpS-59.79
PEG (NY)1.58
PEG (5Y)2.5
Graham Number93.76
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.77% | ||
| ROE | 72.82% | ||
| ROCE | 17.67% | ||
| ROIC | 15.39% | ||
| ROICexc | 17.86% | ||
| ROICexgc | 61.56% | ||
| OM | 33.57% | ||
| PM (TTM) | 19.47% | ||
| GM | 72.06% | ||
| FCFM | 35.46% |
ROA(3y)7.14%
ROA(5y)8.52%
ROE(3y)118.78%
ROE(5y)104.3%
ROIC(3y)13.04%
ROIC(5y)14.18%
ROICexc(3y)15.77%
ROICexc(5y)17.27%
ROICexgc(3y)75.76%
ROICexgc(5y)77.1%
ROCE(3y)14.97%
ROCE(5y)16.28%
ROICexgc growth 3Y3.26%
ROICexgc growth 5Y-18.2%
ROICexc growth 3Y-8.67%
ROICexc growth 5Y-7.85%
OM growth 3Y-6.36%
OM growth 5Y-7.03%
PM growth 3Y-18.6%
PM growth 5Y-18.28%
GM growth 3Y-2.94%
GM growth 5Y-3.32%
F-Score7
Asset Turnover0.4
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 5.45 | ||
| Debt/FCF | 4.28 | ||
| Debt/EBITDA | 2.97 | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 74.3% | ||
| Profit Quality | 182.08% | ||
| Current Ratio | 1.28 | ||
| Quick Ratio | 0.99 | ||
| Altman-Z | N/A |
F-Score7
WACC8.57%
ROIC/WACC1.8
Cap/Depr(3y)24.77%
Cap/Depr(5y)23.42%
Cap/Sales(3y)3.59%
Cap/Sales(5y)3.31%
Profit Quality(3y)165.92%
Profit Quality(5y)155.23%
High Growth Momentum
Growth
EPS 1Y (TTM)13.79%
EPS 3Y5.02%
EPS 5Y5.97%
EPS Q2Q%1.08%
EPS Next Y9.46%
EPS Next 2Y6.31%
EPS Next 3Y5.32%
EPS Next 5Y4.77%
Revenue 1Y (TTM)10.56%
Revenue growth 3Y8.76%
Revenue growth 5Y7.43%
Sales Q2Q%12.4%
Revenue Next Year9.43%
Revenue Next 2Y5.53%
Revenue Next 3Y4.57%
Revenue Next 5Y3.63%
EBIT growth 1Y93.73%
EBIT growth 3Y1.84%
EBIT growth 5Y-0.13%
EBIT Next Year42.71%
EBIT Next 3Y11.36%
EBIT Next 5Y7.69%
FCF growth 1Y36%
FCF growth 3Y7.44%
FCF growth 5Y4.03%
OCF growth 1Y24.04%
OCF growth 3Y7.45%
OCF growth 5Y4.66%
AMGEN INC / AMGN FAQ
Can you provide the ChartMill fundamental rating for AMGEN INC?
ChartMill assigns a fundamental rating of 5 / 10 to AMGN.
What is the valuation status of AMGEN INC (AMGN) stock?
ChartMill assigns a valuation rating of 6 / 10 to AMGEN INC (AMGN). This can be considered as Fairly Valued.
What is the profitability of AMGN stock?
AMGEN INC (AMGN) has a profitability rating of 7 / 10.
How financially healthy is AMGEN INC?
The financial health rating of AMGEN INC (AMGN) is 3 / 10.
What is the earnings growth outlook for AMGEN INC?
The Earnings per Share (EPS) of AMGEN INC (AMGN) is expected to grow by 9.46% in the next year.